Search

The incidence of nonmelanoma skin cancer is increasing every year. Basal cell carcinoma and squamous cell carcinoma are the two major types of nonmelanoma skin cancer. Among other factors, understanding the potential role of nutrients in the development, progression, and treatment of nonmelanoma skin cancer is critical. This contribution provides a review of the nutrients that have been more extensively investigated in the literature with regard to nonmelanoma skin cancer, including dietary fats, retinol, carotenoids, vitamin C, vitamin D, vitamin E, selenium, copper, iron, zinc, green tea, and black tea.

Mohs micrographic surgery (MMS) is very successful in the treatment of nonmelanoma skin cancer. Examining 100% of the margin using MMS improves cure rates. This method has obvious appeal in treating melanoma. Evaluating the lateral margins of melanomas using frozen tissue sections is complicated. Some studies have shown that basic frozen sections can be accurate in margin evaluation, but others have shown that they are unreliable. The use of immunostains on frozen sections is one method that may make the analysis of frozen sections more accurate. Other modifications, including the use of rush paraffin sections in lieu of frozen sections, "slow Mohs," have also been reported. Although the role of MMS in the treatment of melanoma has been controversial, multiple reports using all of the above-mentioned methods have shown great success. Mohs micrographic surgery has a role in the management of melanoma, especially for lesions with poorly defined margins or for those located in areas where tissue conservation is critical.

Merkel cell carcinoma (MCC) is an uncommon, potentially lethal, cutaneous tumor that mainly occurs in sun-exposed skin of the head and neck area of the elderly. We report a case of MCC presenting as a 2-mm crusted erosion on the nose of an elderly patient, the smallest MCC reported thus far in the literature. The optimal management of MCC has not been clearly established. In view of its high local recurrence rate, predilection to metastasis, and significant mortality, aggressive treatment has been advocated. Identification of this tumor at such a small size posed a management dilemma because of lack of prospective treatment data involving biologic markers of prognostic significance for MCC.